| __timestamp | Amphastar Pharmaceuticals, Inc. | Viatris Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 159205000 | 4050200000 |
| Thursday, January 1, 2015 | 174172000 | 5047100000 |
| Friday, January 1, 2016 | 150976000 | 6078400000 |
| Sunday, January 1, 2017 | 149380000 | 6931500000 |
| Monday, January 1, 2018 | 187681000 | 6861900000 |
| Tuesday, January 1, 2019 | 190434000 | 7056300000 |
| Wednesday, January 1, 2020 | 206506000 | 8149300000 |
| Friday, January 1, 2021 | 238029000 | 12310800000 |
| Saturday, January 1, 2022 | 250127000 | 9765700000 |
| Sunday, January 1, 2023 | 293274000 | 8988300000 |
Infusing magic into the data realm
In the ever-evolving pharmaceutical industry, understanding cost structures is crucial for investors and stakeholders. This analysis delves into the cost of revenue trends for Viatris Inc. and Amphastar Pharmaceuticals, Inc. from 2014 to 2023. Over this period, Viatris Inc. consistently reported higher costs, peaking in 2021 with a staggering 12.3 billion USD, reflecting its expansive operations. In contrast, Amphastar Pharmaceuticals, Inc. maintained a more modest cost profile, with a notable increase of 84% from 2014 to 2023, reaching approximately 293 million USD. This disparity highlights Viatris's larger scale and market reach compared to Amphastar's focused approach. The data underscores the importance of strategic cost management in maintaining competitive advantage in the pharmaceutical sector. As the industry faces new challenges, these insights provide a window into the financial dynamics shaping these companies' futures.
Cost of Revenue Trends: Bristol-Myers Squibb Company vs Amphastar Pharmaceuticals, Inc.
Analyzing Cost of Revenue: Teva Pharmaceutical Industries Limited and Amphastar Pharmaceuticals, Inc.
Analyzing Cost of Revenue: Viatris Inc. and Lantheus Holdings, Inc.
Cost of Revenue Trends: Viatris Inc. vs HUTCHMED (China) Limited
Cost Insights: Breaking Down Viatris Inc. and Agios Pharmaceuticals, Inc.'s Expenses
Cost of Revenue Comparison: Viatris Inc. vs Wave Life Sciences Ltd.
Cost of Revenue Comparison: Intra-Cellular Therapies, Inc. vs Amphastar Pharmaceuticals, Inc.
Dr. Reddy's Laboratories Limited vs Amphastar Pharmaceuticals, Inc.: Efficiency in Cost of Revenue Explored
Cost of Revenue: Key Insights for Telix Pharmaceuticals Limited and Amphastar Pharmaceuticals, Inc.
Comparing Cost of Revenue Efficiency: Amneal Pharmaceuticals, Inc. vs Amphastar Pharmaceuticals, Inc.
Cost of Revenue Comparison: Perrigo Company plc vs Amphastar Pharmaceuticals, Inc.
Cost of Revenue: Key Insights for Amphastar Pharmaceuticals, Inc. and MiMedx Group, Inc.